Premium
Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis.
Author(s) -
Borne BE,
Landewe RB,
Goei The HS,
Mattie H,
Breedveld FC,
Dijkmans BA
Publication year - 1995
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1995.tb04425.x
Subject(s) - bioavailability , rheumatoid arthritis , medicine , cmax , confidence interval , capsule , pharmacology , significant difference , pharmacokinetics , gastroenterology , biology , botany
The relative bioavailability of cyclosporin A (CsA) from a new microemulsion oral formulation (NEO) and the currently used soft gelatine capsule (SGC) was determined at steady state in 12 patients with rheumatoid arthritis. The AUC(0,12 h) values of cyclosporin A were significantly greater after NEO than SGC (2873 +/‐ 848 ng ml‐1 h (mean +/‐ s.d.) vs 2355 +/‐ 1128 ng ml‐1 h; P = 0.02, 95% CI (confidence interval of the difference: 81 to 955 ng ml‐1 h). Cmax values were significantly higher after NEO than after SGC (811 +/‐ 244 ng ml‐1 vs 495 +/‐ 291 ng ml‐1, P < 0.0001, 95% CI of the difference: 209 to 422 ng ml‐1).